Correlation between platelet/lymphocyte ratio, neutrophil/lymphocyte ratio and response to neoadjuvant chemoradiation therapy in rectal cancer.

Picardo, Sarah; Teo, MinYuen; Jalil, Khairun Izlinda Abdul; Naqvi, Syed Yaseen; Morris, Patrick G.; Breathnach, Oscar S.; Grogan, William; Leonard, Gregory D.; Hennessy, Bryan T.

doi:10.1200/jco.2016.34.15_suppl.e15140

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the tumor response (Picardo et al, 2016). Recently, other teams from Turkey and Japan reported similar findings and concluded that pre-NLR is not a predictor for pathologic tumor response (Ergen et al, 2021;Ishikawa et al, 2020).…”

Section: Discussionmentioning

confidence: 72%

“…Previous evidence has demonstrated conflicting results regarding the association between pre-NLR and pathologic response to neoCRT in LARC; some studies assigned a predictive role (Braun et al, 2019;Kim et al, 2014;Shin et al, 2016;Zhang et al, 2019); however, others did not (Ergen et al, 2021;Ishikawa et al, 2020;Jeon et al, 2019;Lai et al, 2020;Picardo et al, 2016).…”

Section: Discussionmentioning

confidence: 97%

“…The value of NLR taken before neoCRT (henceforth called pre-NLR) in predicting the pathologic response in LARC is still a matter of debate; several studies assigned a predictive role for it (Braun et al, 2019;Kim et al, 2014;Shin et al, 2016;X Zhang et al, 2019); however, several others did not (Ergen et al, 2021;Ishikawa et al, 2020;Jeon et al, 2019;Lai et al, 2020;Picardo et al, 2016). This discrepancy might originate from the retrospective nature of studies available in the literature with their inherent limitations, such as selection bias and miss to control the effect of confounding factors.…”

Section: Neutrophil-to-lymphocyte Ratio (Nlr) As a Poor Predictive Bi...mentioning

confidence: 99%

See 2 more Smart Citations

Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study

Novin

Fadavi

Mortazavi

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background:The literature is inconsistent for the role of neutrophil-to-lymphocyte ratio (NLR) obtained before neoadjuvant therapy (pre-NLR) in predicting pathological response to neoadjuvant chemoradiation (neoCRT) in patients with locally advanced rectal cancer (LARC). In the present cohort study, we explored the predictive role of pre-NLR in this setting. Methods: We prospectively included patients with LARC who were candidates for neoCRT at the Shohada-e-Hafte Tir Hospital (Tehran, Iran) between Mar 2018 and Feb 2020. The pre-NLR was obtained through a peripheral blood smear before CRT. We used the AJCC system for evaluating tumor regression grade (TRG). The TRGs were categorized into: response-group 1 (TRG 0-1 vs. 2-3), response-group 2 (TRG 0 vs. 1-3), and responsegroup 3 (TRG 0-2 vs. 3). We applied receiver operating characteristic (ROC) analysis to assess the predictive value of pre-NLR. Results: Of the 86 screened patients with rectal cancer, 30 patients who fulfilled the inclusion criteria were included in the study. In total, 63.3% were responsive, and 23.3% had complete pathologic response. Pre-NLR could not predict the pathologic response in response-group 1 (area under the ROC curve [AUC]: 0.45, 95%CI 0.23-0.66) and response-group 2 (AUC: 0.36, 95%CI 0.13-0.59). Nevertheless, it had a poor predictive value in response-group 3 (AUC: 0.55, CI%95 0.33-0.75) with an optimal NLR cutoff value of 2.94. Conclusions: Pre-NLR could not predict the pathological response to neoCRT in our cohort of patients with LARC.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 97%

Section: Neutrophil-to-lymphocyte Ratio (Nlr) As a Poor Predictive Bi...mentioning

confidence: 99%

See 1 more Smart Citation

Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study

Novin

Fadavi

Mortazavi

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Additionally, Shen et al ( 29 ) reported that there was no significant association between tumor response and NLR to nCRT. It has previously been reported that baseline systemic inflammatory responses could not predict tumor responses in colorectal cancer ( 32 , 33 ). In the present study, there was no significant association between pCR and NLR or PLR during nCRT.…”

Section: Discussionmentioning

confidence: 96%

Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer

et al. 2020

View full text Add to dashboard Cite

Systemic inflammatory responses are associated with the prognosis of patients with colorectal cancer. However, the value in predicting tumor responses to neoadjuvant chemoradiotherapy (nCRT) remains to be elucidated. The current study aimed to investigate the association between systemic inflammatory indices and pathological complete response (pCR). The training and validation cohorts included 225 and 96 patients with locally advanced rectal cancer. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio were recorded prior to nCRT and radical surgery. Univariate and multivariate analysis were used to investigate the association between systemic inflammatory indices and pCR. Systemic inflammatory indices prior to or following treatment had no significant association with pCR; however, the percentage change in NLR from pre-nCRT to post-nCRT was associated with a poor response, and a percentage change of >21.5% NLR (P=0.006; OR=0.413; 95% CI=0.22–0.773) was a predictor of poor pCR. Therefore, in rectal cancer, the percentage change in NLR from pre- to post-nCRT was found to be a predictor of poor pCR.

show abstract

“…Among these, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are two readilyavailable serologic biomarkers which are felt to be surrogates for the degree of systemic inflammation and have been studied as prognostic markers in a range of malignancies [19,20]. Previous studies have yielded conflicting results as to their prognostic/predictive potential in rectal cancer [19][20][21][22][23][24][25][26][27][28], though few studies have compared the roles of NLR and PLR in the same cohort. We conducted a multi-institutional review to assess the ability of NLR and PLR to predict prognosis and likelihood of response in patients with LARC treated with nCRT.…”

Section: Introductionmentioning

confidence: 99%

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.

Dudani

Marginean

Tang

et al. 2017

JCO

View full text Add to dashboard Cite

758 Background: A standard therapy for locally advanced rectal cancer (LARC) includes fluoropyrimidine (FP)-based neoadjuvant chemoradiation (nCRT). Previous studies have inconsistently demonstrated that baseline neutrophil- and platelet-to-lymphocyte ratios (NLR and PLR) are predictive of response to nCRT or prognostic of outcomes in LARC. Methods: We performed a review of patients with LARC undergoing nCRT followed by surgery with curative intent from 2005-2013 in 3 academic cancer centers from 2 Canadian provinces. Data regarding demographics, staging, baseline hematologic variables (<4 weeks prior/up to 2 weeks after initiating nCRT) and treatment details were collected. Outcome measures of interest were pathological complete response (pCR), disease-free survival (DFS) and overall survival (OS). Logistic regression and Cox proportional hazard models were used to assess for an association between baseline hematologic variables and outcomes. Results: Of 1081 identified patients, 845 were included in the DFS/OS analysis. Median age was 61 (range 23-87), 70% male, 85% performance status (PS) 0-1. 31% and 67% had clinical stage II and III disease, respectively. 25% had elevated NLR (≥ 4), and 64% had elevated PLR (≥ 150). 98% of patients received FP-based nCRT, with 96% receiving ≥ 44 Gy (median 50 Gy [range 20-74]). 80% completed neoadjuvant chemotherapy and 94% completed neoadjuvant radiotherapy, with a pCR rate of 23%. After a median follow up time of 64 months, 6% developed local recurrence, 20% developed distant recurrence and 19% have died. 5-year OS and DFS were 78% (95% CI 74-81%) and 76% (95% CI 73-79%), respectively. In multivariate analyses, elevated baseline NLR and PLR were not prognostic for OS or DFS. Elevated NLR was a negative predictor of pCR (OR 0.61, p=0.037, 95% CI 0.38-0.97); there was no association with elevated PLR. Conclusions: Elevated NLR was a negative predictor of pCR, but not prognostic for DFS and OS. PLR was neither predictive nor prognostic.

show abstract

Correlation between platelet/lymphocyte ratio, neutrophil/lymphocyte ratio and response to neoadjuvant chemoradiation therapy in rectal cancer.

Cited by 4 publications

References 0 publications

Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study

Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study

Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.

Contact Info

Product

Resources

About